D. Marx

Immunotherapy with dendritic cells as a second-line therapy in advanced pleural mesothelioma.

e13063 Background: Malignant pleural mesothelioma (MPM) is an aggressive disease with an unfavorable prognosis. The current front-line treatment for nonoperable stages is cisplatinum in combination with pemetrexed chemotherapy. The reported median overall survival times are less than 15 months. After failure of first-line therapy there is currently no proven effective therapy, whereas potential side effects from further treatments may impair quality of life. In those cases, we report that immunotherapy with monocyte-derived dendritic cells (MoDC) can be effective without significant impact on life quality. Methods: After isolating monocytes from peripheral blood of n=14 patients with stage 4 MPM who failed first-line chemotherapy, MoDC were generated using standard protocols. The MoDC were primed on day 5 with tumor-lysate and co-cultured with toll-like receptor ligands to induce a TH1-polarization of the MoDC. In one case, an allogeneic cell line lysed by the oncolytic Newcastle disease virus (NDV) was u...